Several other brokerages also recently issued reports on AGN. Mizuho reaffirmed a buy rating and issued a $305.00 price objective on shares of Allergan PLC in a research report on Wednesday, September 14th. Piper Jaffray Cos. reaffirmed a hold rating and issued a $236.00 price objective on shares of Allergan PLC in a research report on Saturday, June 18th. Credit Suisse Group AG set a $322.00 target price on Allergan PLC and gave the company a hold rating in a research note on Wednesday, August 3rd. Vetr cut Allergan PLC from a strong-buy rating to a buy rating and set a $275.94 target price for the company. in a research note on Thursday, June 2nd. Finally, Leerink Swann reiterated a buy rating on shares of Allergan PLC in a research note on Thursday, June 30th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Allergan PLC currently has an average rating of Buy and an average price target of $308.54.
Shares of Allergan PLC (NYSE:AGN) traded up 1.08% during trading on Wednesday, hitting $240.99. 407,733 shares of the stock were exchanged. The firm has a 50 day moving average of $245.19 and a 200-day moving average of $243.01. Allergan PLC has a 12-month low of $195.50 and a 12-month high of $322.68. The company has a market cap of $95.42 billion, a price-to-earnings ratio of 22.94 and a beta of 0.73.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The company earned $3.68 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the company earned $4.41 earnings per share. Allergan PLC’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, analysts forecast that Allergan PLC will post $14.01 earnings per share for the current year.
Institutional investors have recently modified their holdings of the company. Evercore Wealth Management LLC boosted its position in shares of Allergan PLC by 26.2% in the second quarter. Evercore Wealth Management LLC now owns 153,392 shares of the company’s stock worth $35,448,000 after buying an additional 31,821 shares in the last quarter. Carnick & Kubik Group LLC bought a new position in shares of Allergan PLC during the second quarter worth $989,000. Williams Jones & Associates LLC boosted its position in shares of Allergan PLC by 1.1% in the second quarter. Williams Jones & Associates LLC now owns 110,544 shares of the company’s stock worth $25,546,000 after buying an additional 1,242 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Allergan PLC during the second quarter worth $3,691,000. Finally, Kentucky Retirement Systems bought a new position in shares of Allergan PLC during the second quarter worth $7,773,000. 85.19% of the stock is currently owned by hedge funds and other institutional investors.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.